Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles

Biomaterials

Volumn 35, Issue 18, 2014, Pages 5028-5038

  Feng, Qiang ^a   Yu, Min Zhi ^a   Wang, Jian Cheng ^a   Hou, Wen Jie ^a   Gao, Ling Yan ^a   Ma, Xiao Fei ^a   Pei, Xi Wei ^a   Niu, Yu Jie ^a   Liu, Xiao Yan ^a   Qiu, Chong ^a   Pang, Wen Hao ^a   Du, Li Li ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Co delivery; Core shell nanoparticle; Paclitaxel; Tumor targeting therapy; Vapreotide; VEGF targeted siRNA

Indexed keywords

CELL ENGINEERING; CYTOLOGY; DISEASES; DRUG DELIVERY; ENDOTHELIAL CELLS; NANOPARTICLES; SHELLS (STRUCTURES); TUMORS;

CO DELIVERIES; CORE-SHELL NANOPARTICLES; PACLITAXEL; TUMOR TARGETING; VAPREOTIDE; VEGF TARGETED SIRNA;

GENE THERAPY;

NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA; SOMATOSTATIN RECEPTOR; VAPREOTIDE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; SOMATOSTATIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG UPTAKE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; TUMOR GROWTH; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CELL CYCLE; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; GENETICS; MCF 7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUDE MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE; DOWN-REGULATION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; PACLITAXEL; RECEPTORS, SOMATOSTATIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SOMATOSTATIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897914852     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.012     Document Type: Article

References (36)

1. Siemann D.W., Rojiani A.M. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002, 54:1512-1517.
2. Bilenker J.H., Flaherty K.T., Rosen M., Davis L., Gallagher M., Stevenson J.P., et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005, 11:1527-1533.
3. Li L., Rojiani A.M., Siemann D.W. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002, 41:91-97.
4. Nelkin B.D., Ball D.W. Combretastatin A-4 and doxorubicin combination treatment is effective in a preclinical model of human medullary thyroid carcinoma. Oncol Rep 2001, 8:157-160.
5. Zhang Y.-f., Wang J.-c., Bian D.-y., Zhang X., Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm 2010, 74:467-473.
6. Wang Y., Yang T., Wang X., Dai W., Wang J., Zhang X., et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release 2011, 149:299-306.
7. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
8. Kim D.H., Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007, 8:173-184.
9. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
10. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
11. Claffey K.P., Robinson G.S. Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis. Cancer Metastasis Rev 1996, 15:165-176.
12. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J Control Release 2008, 129:107-116.
13. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004, 64:3365-3370.
14. Zhang J., Wu Y.O., Xiao L., Li K., Chen L.L., Sirois P. Therapeutic potential of RNA interference against cellular targets of HIV infection. Mol Biotechnol 2007, 37:225-236.
15. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
16. Li S.D., Huang L. Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci 2006, 1082:1-8.
17. Chono S., Li S.D., Conwell C.C., Huang L. An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release 2008, 131:64-69.
18. Yang T., Zhao Z.-X., Xu Z.-Z., Zhao E.-Y., Liu X.-Y., Chen C.-J., et al. Tumor targeted delivery of siRNA by surface-modified LPC nanoparticles. J Chin Pharm Sci 2011, 7.
19. Bruns C., Weckbecker G., Raulf F., Kaupmann K., Schoeffter P., Hoyer D., et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci 1994, 733:138-146.
20. Kumar U., Grigorakis S.I., Watt H.L., Sasi R., Snell L., Watson P., et al. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005, 92:175-186.
21. Kahan Z., Nagy A., Schally A.V., Hebert F., Sun B., Groot K., et al. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 1999, 82:592-598.
22. Zhang J., Jin W., Wang X., Wang J., Zhang X., Zhang Q. A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models. Mol Pharmacol 2010, 7:1159-1168.
23. Zheng N., Dai W., Du W., Zhang H., Lei L., Wang X., et al. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. Mol Pharmacol 2012, 9:1175-1188.
24. Coy D.H., Taylor J.E. Receptor-specific somatostatin analogs: correlations with biological activity. Metabolism 1996, 45:21-23.
25. Weckbecker G., Raulf F., Stolz B., Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993, 60:245-264.
26. Yuan M., Wang J., Deng J., Wang Z., Yang W., Li G., et al. Combination therapy in A549 cells. Nucl Med Biol 2010, 37:317-326.
27. Sarr M.G. The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg 2003, 196:556-564. discussion 64-5; author reply 65.
28. Wang X., Wang Y., Chen X., Wang J., Zhang X., Zhang Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release 2009, 139:56-62.
29. Kim S.C., Yu J., Lee J.W., Park E.S., Chi S.C. Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution). J Pharm Biomed Anal 2005, 39:170-176.
30. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
31. Schadlich A., Rose C., Kuntsche J., Caysa H., Mueller T., Gopferich A., et al. How stealthy are PEG-PLA nanoparticles? an NIR in vivo study combined with detailed size measurements. Pharm Res 2011, 28:1995-2007.
32. Brown D.A., London E. Structure and origin of ordered lipid domains in biological membranes. J Membr Biol 1998, 164:103-114.
33. Safinya C.R. Structures of lipid-DNA complexes: supramolecular assembly and gene delivery. Curr Opin Struct Biol 2001, 11:440-448.
34. Lopes N.M., Adams E.G., Pitts T.W., Bhuyan B.K. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993, 32:235-242.
35. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
36. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.